Kaposi's sarcoma natural history: Difference between revisions
Created page with "{{CMG}} {{Kaposi's sarcoma}} ==Overview== With the decrease in the death rate among AIDS patients receiving new treatments in the 1990s, the incidence and severity of epidemi..." |
Hudakarman (talk | contribs) No edit summary |
||
| (20 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
{{CMG}} | __NOTOC__ | ||
{{CMG}}; {{AE}} {{Rim}} {{ADS}} {{Hudakarman}} | |||
{{Kaposi's sarcoma}} | {{Kaposi's sarcoma}} | ||
==Overview== | ==Overview== | ||
The [[prognosis]] of Kaposi's sarcoma (KS) depends on its [[histological]] type, whether the [[cancer]] has spread, and the general health status of the [[patient]]. When stratified by [[age]], the 5-year relative [[survival]] of [[patients]] with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of [[age]] respectively. | |||
==Natural | ==Natural History== | ||
[[Kaposi's sarcoma-associated herpesvirus]] (KSHV) [[infection]] does not always lead to KS; it is still unclear what other factors may be required, such as preexisting [[immune system]] damage, or a specific interaction with [[HIV]] or other [[viruses]]. However, [[research]] in Africa has shown that even in the absence of [[HIV AIDS|HIV]]/[[AIDS]], KS is more common in men than women although KSHV infection is equal between both sexes. This suggests that [[sex hormone]]s may either protect from or predispose to KS in persons infected with the [[virus]]. Growth can range from very slow to explosively fast, and be associated with significant [[mortality]] and [[morbidity]].<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | |||
== | ==Prognosis== | ||
The [[prognosis]] of Kaposi's sarcoma depends on the following: | |||
* The type of Kaposi sarcoma | |||
* Whether the [[cancer]] has spread | |||
* Whether the [[cancer]] has just been [[Diagnosis|diagnosed]] or has recurred | |||
* The patient's general [[health]], especially the [[immune system]] | |||
===5-Year Survival=== | |||
* Between 2004 and 2010, the 5-year relative [[Survival rate|survival]] of [[patients]] with Kaposi sarcoma was 72%.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | |||
= | * When stratified by [[age]], the 5-year relative [[Survival rates|survival]] of [[patients]] with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of [[age]] respectively.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | |||
[[Category:HIV/AIDS]] | |||
[[Category:Types of cancer]] | |||
[[Category:Dermatology]] | |||
[[Category:Pulmonology]] | |||
[[Category:Gastroenterology]] | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Vascular medicine]] | |||
[[Category:Surgery]] | |||
Latest revision as of 14:00, 10 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Amandeep Singh M.D.[3] Huda A. Karman, M.D.
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma natural history On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma natural history |
|
Risk calculators and risk factors for Kaposi's sarcoma natural history |
Overview
The prognosis of Kaposi's sarcoma (KS) depends on its histological type, whether the cancer has spread, and the general health status of the patient. When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.
Natural History
Kaposi's sarcoma-associated herpesvirus (KSHV) infection does not always lead to KS; it is still unclear what other factors may be required, such as preexisting immune system damage, or a specific interaction with HIV or other viruses. However, research in Africa has shown that even in the absence of HIV/AIDS, KS is more common in men than women although KSHV infection is equal between both sexes. This suggests that sex hormones may either protect from or predispose to KS in persons infected with the virus. Growth can range from very slow to explosively fast, and be associated with significant mortality and morbidity.[1]
Prognosis
The prognosis of Kaposi's sarcoma depends on the following:
- The type of Kaposi sarcoma
- Whether the cancer has spread
- Whether the cancer has just been diagnosed or has recurred
- The patient's general health, especially the immune system
5-Year Survival
- When stratified by age, the 5-year relative survival of patients with Kaposi sarcoma was 68.6% and 87.5% for patients <65 and ≥ 65 years of age respectively.[1]
References
- ↑ 1.0 1.1 1.2 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.